We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




AI-Driven Prognostic Test Assesses Risk of Early Kidney Transplant Rejection

By LabMedica International staff writers
Posted on 05 Jul 2023

Existing methods of classifying patients as low-risk or high-risk for rejection while awaiting transplantation rely on generic factors such as race, retransplantation, recipient's age, and the presence of antibodies against frequent donors. More...

Now, a novel test utilizes an RNA gene signature to help determine an individual patient's risk for acute rejection during the pre-transplant assessment for a kidney transplant. This can enable clinicians to accurately determine a patient’s immunosuppression level in a more personalized way.

Verici Dx’s (Franklin, TN, USA) Clarava is a pre-transplant prognostic test designed to evaluate a patient's immune response and determine the risk of early kidney transplant rejection. The test employs RNA sequencing and artificial intelligence to determine an RNA signature from gene expression. Identifying RNA signatures related to graft tolerance might also present opportunities to discover new biological markers or therapeutic targets, thereby personalizing immunosuppressant therapy. The synergy of next-generation RNA sequencing and deep learning provides crucial molecular insights for understanding the mechanisms behind kidney graft tolerance. Armed with this knowledge, advanced machine learning algorithms can be utilized for making accurate prognoses or diagnoses about kidney transplants, ultimately improving patient outcomes—all through a single blood sample. Using just a simple blood draw, Clarava can help clinicians to treat millions of eligible patients each year upon its commercial launch before the end of 2023.

Verici has reported positive validation results from its prospective, blinded, clinical validation study for Clarava. The study involved 122 patients from a wide and diverse range of backgrounds who were preparing for a kidney transplant, and who had various rejection outcomes. Conducted across 13 centers in the US, Europe, and Australia, the study showed a sensitivity of 78% and specificity of 64% in identifying patients at an increased risk for kidney rejection during the critical 60 to 90 days post-transplant after receiving a kidney from a deceased donor. The analysis of its clinical performance revealed that the test could distinguish between high-risk and low-risk patients, with high-risk patients being approximately six times more likely to experience rejection.

Related Links:
Verici Dx


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Slide Scanner
VENTANA DP 600
New
Myocardial Infarction Test
Finecare cTn I/NT-proBNP Rapid Quantitative Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: This image shows a second-generation version of the device that can also measure cell morphology (Photo courtesy of MIT)

Rapid Cell Density Measurement Technique to Help Predict Immunotherapy Response

The density of a cell provides valuable insights into its condition. As cells go through processes such as proliferation, differentiation, or cell death, they may gain or lose water and other molecules,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.